The Effect of Intravitreal Bevacizumab Injection in Eales' Disease.
10.3341/jkos.2009.50.10.1595
- Author:
Sang Won MOON
1
;
Yumi SONG
;
Hee Yoon CHO
;
Byung Ro LEE
;
Jun Hong SOHN
;
Young Sook PARK
Author Information
1. Department of Ophthalmology, College of Medicine, Hanyang University Hospital, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Eales' disease;
Intravitreal bevacizumab injection;
Laser photocoagulation
- MeSH:
Antibodies, Monoclonal, Humanized;
California;
Eye;
Fluorescein Angiography;
Follow-Up Studies;
Humans;
Light Coagulation;
Male;
Phlebitis;
Retina;
San Francisco;
Vitreous Hemorrhage;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2009;50(10):1595-1599
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To report on 2 cases of Eales' disease that were successfully regressed with laser photocoagulation and intravitreal bevacizumab (Avastin; Genetech, Inc, San Francisco, California, USA) injection. CASE SUMMARY: Two male patients (30 years and, 40 years of age,) with a history of recurrent vitreous hemorrhage were diagnosed with Eales' disease. The 2 patients had peripheral retina neovascularization and active phlebitis in fundus fluorescein angiography. No other findings were observed in their eyes in the general examination. Scatter laser photocoagulation and intravitreal bevacizumab injection were performed. After 1 month follow-up, neovascularization completely regressed. There was no complication or recurrent vitreous hemorrhage at the 1 year follow up. CONCLUSIONS: Intravitreal bevacizumab injection, as combination treatment of laser photocoagulation, may be helpful in the regression of neovascularization due to Eales' disease.
